Free Trial
Kelly Shi

Kelly Shi Analyst Performance

Senior Vice President, Senior Research Analyst at Jefferies Financial Group

Kelly Shi is a stock analyst at Jefferies Financial Group in the medical sector, covering 10 publicly traded companies. Over the past year, Kelly Shi has issued 13 stock ratings, including and buy recommendations. While full access to Kelly Shi's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kelly Shi's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
16 Last 1 Years
Buy Recommendations
93.33% 14 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy93.3%14 ratings
Hold0.0%0 ratings
Sell6.7%1 ratings

Out of 15 total stock ratings issued by Kelly Shi at Jefferies Financial Group, the majority (93.3%) have been Buy recommendations, followed by 6.7% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
10 companies

Kelly Shi, an analyst at Jefferies Financial Group, currently covers 10 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
100.0%

Kelly Shi of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
90.0%
MED - DRUGS
1 company
10.0%

Kelly Shi's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3/16/2026Initiated Coverage$230.36$290.00Buy
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3/16/2026Initiated Coverage$80.73$110.00Buy
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
1/7/2026Reiterated Rating$22.94$31.00Buy
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
12/17/2025Reiterated Rating$18.66$22.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
12/12/2025Boost Price Target$2.30$9.00Buy
Insmed, Inc. stock logo
INSM
Insmed
12/10/2025Set Price Target$194.59$269.00
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
12/9/2025Boost Price Target$87.30$122.00Buy
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
11/4/2025Reiterated Rating$60.99$73.00Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
10/28/2025Boost Price Target$67.88$77.00Buy
Insmed, Inc. stock logo
INSM
Insmed
8/13/2025Boost Price Target$122.00$148.00Buy
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7/7/2025Boost Price Target$9.40$28.00Buy
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
6/25/2025Set Price Target$46.38$64.00Buy
Insmed, Inc. stock logo
INSM
Insmed
5/13/2025Initiated Coverage$67.75$105.00Buy
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4/25/2025Set Price Target$25.82$44.00Buy
Verastem, Inc. stock logo
VSTM
Verastem
4/10/2025Initiated Coverage$5.28$15.00Buy
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
3/25/2025Reiterated Rating$3.41$1.00Underperform